Acellbia vs HLX01

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline

Acellbia

Marketed by Biocad

Phase 3 in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02744196 · Phase 3 · completed

This was a randomized, triple-blinded, placebo-controlled trial with 159 patients and a validated disease-response primary endpoint (ACR20). The result was clearly positive: 65.7% of Acellbia-treated patients achieved ACR20 at week 24 versus 29.4% on placebo (p<0.0001).

Reported efficacy

Percentage of patients who developed ACR20 response on 24 week of therapy (Week 24): ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%) (met)

Result source: NCT02744196

HLX01 · Hanlikang

Marketed by Shanghai Henlius Biotech

Phase 3 in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT03522415 · Phase 3 · completed

This randomised, quadruple-blind trial compared HLX01 plus methotrexate with placebo plus methotrexate in 275 patients with rheumatoid arthritis. At 24 weeks, 60.7% of patients on HLX01 reached an ACR20 response against 35.9% on placebo (P<0.001), a clear result on a validated measure of disease activity.

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAcellbiaHLX01
ACR2065.7% vs 29.4%a+36.3 vs placebowk 24NCT0274419660.7% vs 35.9%a+24.8 vs placebowk 24NCT03522415
ACR50—Not posted · NCT02744196—Not posted · NCT03522415
ACR70—Not posted · NCT02744196—Not posted · NCT03522415
DAS28-CRP remission—Not posted · NCT02744196—Not posted · NCT03522415
HAQ-DI, change—Not posted · NCT02744196—Not posted · NCT03522415
Modified Sharp score, change—Not posted · NCT02744196—Not posted · NCT03522415

ACR20

Acellbia
65.7% vs 29.4%a+36.3 vs placebowk 24NCT02744196
HLX01
60.7% vs 35.9%a+24.8 vs placebowk 24NCT03522415

ACR50

Acellbia
—Not posted · NCT02744196
HLX01
—Not posted · NCT03522415

ACR70

Acellbia
—Not posted · NCT02744196
HLX01
—Not posted · NCT03522415

DAS28-CRP remission

Acellbia
—Not posted · NCT02744196
HLX01
—Not posted · NCT03522415

HAQ-DI, change

Acellbia
—Not posted · NCT02744196
HLX01
—Not posted · NCT03522415

Modified Sharp score, change

Acellbia
—Not posted · NCT02744196
HLX01
—Not posted · NCT03522415
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acellbia's landscape · HLX01's landscape